Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q3 2025 · 10-Q
Revenue$191.84M$191.84M+0.3% vs Q3 2024 Net Income$17.35M$17.35M−57.1% vs Q3 2024 EPS Diluted$0.37$0.37−52.6% vs Q3 2024 Gross Profit$98,646,000−3.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flowderived$52,583,000−12.3% Free Cash Flowderived$47,235,000+2.3% Margins · derivedGross margin51.4%−1.9 pt vs Q3 2024
Operating margin13.2%−16.6 pt vs Q3 2024
Net margin9.0%−12.1 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 6, 2025 · 37 d after period end